S107 A Readmission Predictor Model to Identify High-Risk Patients With Crohn’s Disease

currently undergoing evaluation for bone marrow transplantation. Discussion: We report, what we believe, the first documented case of AML in a blast crisis with a patient on ustekinumab for UC. Though the patient was undergoing treatment with ustekinumab for 5 months prior to AML diagnosis, she had an extended history of being on immunosuppressive therapy including prednisone and azathioprine. IBD itself has been seen to have a higher association with gastrointestinal malignancy due to chronic intestinal inflammation. However, recent studies have demonstrated extra-intestinal occurrences such as non-Hodgkin lymphoma, urothelial carcinoma, and prostate cancer. In a single center study, all IBD patients who developed a malignancy had received immunosuppressive therapy at some point in their IBD treatment. Although we cannot directly link the cause of AML to being on ustekinumab, there may be a relation of her chronic immunosuppression to this finding. With the relatively recent addition of ustekinumab in the treatment of moderate to severe IBD, this case provides useful information that patients and medical providers should remain aware of in their decision making.